Skip to main content

Geisinger becomes the first member of Risant Health

In 2023, we sent over 75,000 home test kits to members who are managing diabetes or at risk for chronic kidney disease or colorectal cancer. It’s all part of our at-home screening initiative — helping members get needed tests and closing potential gaps in care.

Helping members manage diabetes and kidney health

Annual hemoglobin A1c and urine albumin screenings can help in managing diabetes and kidney health. Consistent monitoring of glycemic control leads to better outcomes for patients with diabetes and early detection of abnormal amounts of urine albumin can prevent the onset of chronic kidney disease. That’s why in 2023, we sent thousands of hemoglobin A1c (HbA1c), urine albumin (uACR) and estimated glomerular filtration rate (eGFR) screening kits to at-risk members.

Early detection of colorectal cancer saves lives

Early detection is key in the fight against colorectal cancer. Around 4,600 members completed an at-home screening test last year, and over 680 of those came back positive. This simple test can help save lives.

Through our member outreach we emphasized the importance of these tests. The kits contain all the supplies members need and clear instructions on how to complete the tests. As always, test results are shared with members’ doctors to coordinate any additional testing or treatment that may be needed.

Prioritize preventive care by talking to your patients about the benefits of at-home test kits. Contact the GHP quality and assurance team at 866-847-1216 or your GHP provider account manager at 800-876-5357 if you have questions about our at-home screening initiatives.

Geisinger Logo
Content from General Links with modal content